Visual estimation of the tumor volume in prostate cancer: A useful means for predicting biochemical-free survival after radical prostatectomy?

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 1, 2007, Pages 66-71

  May, M ^a   Siegsmund, M ^b   Hammermann, F ^b   Loy, V ^b   Gunia, S ^a  

^a Carl Thiem Hospital Cottbus   (Germany)

^b VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REFERENCE VALUE;

ADULT; AGED; CARCINOMA; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 33847645317     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500928     Document Type: Article

References (21)

1. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 2005; 216: 34-63.
2. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332-337.
3. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A requested for a standardized, organ specific methodology. Cancer 2002; 95: 1650-1655.
4. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-459.
5. Taftachi R, Ayhan A, Ekici S, Ergen A, Ozen H. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: A comparison of PCNA and Ki-67. BJU Int 2005; 95: 650-654.
6. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004; 172: 508-511.
7. Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol 2004; 17:349-359.
8. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small volume prostate cancer (<0.5ml) in whole-mount prostatectomy specimens. Mod Pathol 2005; 18: 1022-1026.
9. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993; 149: 1478-1481.
10. Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F et al. Prognostic significance of tumor volume after radical prostatectomy: A multivariate analysis of pathological prognostic factors. Eur Urol 2003; 43: 39-44.
11. Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000; 89: 1308-1314.
12. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer 1996; 78: 337-340.
13. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997; 10: 326-333.
14. Humphrey PA, Frazier HA, Vollmer RT, Paulson DF. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 1993; 71: 1821-1827.
15. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: Application of a grid method to prostatectomy specimens. Hum Pathol 1990; 21: 799-804.
16. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-63.
17. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 1235-1241.
18. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-1400.
19. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: Influence of tumor deoxyribonucleic acid ploidy. J Urol 1989; 142: 1262-1265.
20. Eastham JA, Scardino PT. Radical prostatectomy. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders: Philadelphia, PA, 1989, pp 2547-2564.
21. Humphrey PA, Walther PJ, Currin SM, Vollmer RT. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma.Am J Surg Pathol 1991; 15: 1165-1170.